Carvedilol as a potential novel agent for the treatment of Alzheimer's disease
- 31 December 2011
- journal article
- Published by Elsevier BV in Neurobiology of Aging
- Vol. 32 (12), 2321.e1-2321.e12
- https://doi.org/10.1016/j.neurobiolaging.2010.05.004
Abstract
No abstract availableFunding Information
- NIH (UO1 AG29310)
This publication has 59 references indexed in Scilit:
- Effects of Cardiovascular Medications on Rate of Functional Decline in Alzheimer DiseaseAmerican Journal of Geriatric Psychiatry, 2008
- Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memoryNature Medicine, 2008
- Grape-Derived Polyphenolics Prevent A Oligomerization and Attenuate Cognitive Deterioration in a Mouse Model of Alzheimer's DiseaseJournal of Neuroscience, 2008
- Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer diseaseJCI Insight, 2007
- ??-Adrenoreceptor Antagonists Attenuate Brain Injury After Transient Focal Ischemia in RatsAnesthesia & Analgesia, 2006
- Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse modelNature Medicine, 2006
- Synaptic plasticity disruption by amyloid β protein: modulation by potential Alzheimer's disease modifying therapiesBiochemical Society Transactions, 2005
- Caloric restriction attenuates β‐amyloid neuropathology in a mouse model of Alzheimer's diseaseThe FASEB Journal, 2005
- Natural oligomers of the amyloid-β protein specifically disrupt cognitive functionNature Neuroscience, 2004
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureThe New England Journal of Medicine, 1996